Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma. - Yonemoto, Takuya; Ogasawara, Sadahisa; Kanogawa, Naoya; Miwa, Chihiro; Fujiya, Makoto; Tsuchiya, Takahiro; Sawada, Midori; Akatsuka, Teppei; Izai, Ryo; Yumita, Sae; Nakagawa, Miyuki; Okubo, Tomomi; et al. (Hepatology Research, 2025)